UK Regulatory System Progress And New MedTech Directorate Unveiled At Industry Meeting
More momentum behind post-EU regulatory arrangements at home and globally
In the three months since Brexit, UK medtech stakeholders have seen the beginnings of new regulations, foreign trade plans being put in place, and perhaps new perceptions of medtech’s value.
You may also be interested in...
By utilizing the properties of graphene, INBRAIN hopes to develop improved electrodes implanted in the brain, raising the potential of neuromodulation for treating complex neurological disorders.
The duties of the new commissioner for patient safety have been prioritized in the UK’s Medicines and Medical Devices bill, which has been given Royal Assent.
Reaching deep and being resourceful were the in-demand attributes that medtech industry leaders brought to bear when the COVID-19 pandemic stretched health care providers almost to breaking point.